Trials / Completed
CompletedNCT00591890
Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans
Phase IB Study to Evaluate the Biological Activity of Indibulin Using Positron-Emission Tomography (PET) Scans
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Single arm, open label, Phase IB study of indibulin capsules in subjects with advanced solid tumors; eligible subjects will have a baseline PET scan showing a standardized uptake value (SUV) of ≥5.0 in ≥1 lesion on an 18F-FDG (fluorine-18-labeled deoxyglucose) scale.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | indibulin | dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days. |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-06-01
- Completion
- 2009-03-01
- First posted
- 2008-01-11
- Last updated
- 2012-07-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00591890. Inclusion in this directory is not an endorsement.